Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy

The search for strategic molecular targets among a myriad of cell signaling pathways has long been a cornerstone for both molecular cancer research and gene therapy research, leading to the development of novel cancer therapies that act at the level of the genome (DNA), the transcriptome (RNA), and/or the proteome (protein). In this article, we focus on a pivotal and therapeutically accessible locus of executive cell cycle checkpoint control—focusing specifically on the cyclin G1 protein (CCNG1 proto-oncogene product) and the associated oncogenic drivers arrayed along the aberrant biochemical pathways that promote and ensure uncontrolled cell proliferation, resulting in oncogenesis, increasingly aggressive metastasis, and chemotherapeutic refractoriness.